Burden of Implanted-Device-Detected Atrial High-Rate Episode Is Associated With Future Heart Failure Events - Clinical Significance of Asymptomatic Atrial Fibrillation in Patients With Implantable Cardiac Electronic Devices.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
25 03 2019
Historique:
pubmed: 1 3 2019
medline: 6 5 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

The relationship between atrial high-rate episode (AHRE) burden (i.e., the frequency of atrial tachyarrhythmia) and heart failure (HF) risk is unclear. We hypothesized that new-onset and higher burden of AHRE are associated with HF. Methods and Results: We included 104 consecutive patients with cardiac implantable electronic devices (CIEDs) capable of continuous atrial rhythm monitoring. Patients with AF history were excluded. To stratify patients, AHREs were evaluated only during the initial 1 year after CIED implantation. The primary endpoint was all-cause death or new-onset or worsening HF that required unplanned hospitalization or readjustment of HF drug therapy. At 1 year after CIED implantation, 34/104 patients (33%) exhibited AHREs. No difference in basal clinical characteristics except for left ventricular ejection fraction between patients with and without new-onset AHREs was found. AHRE groups had more HF events than the non-AHRE group. All patients were divided into 3 groups based on AHRE burden: none, low, and high. Worsening HF was observed in 12 patients (12%). Cox hazard analysis revealed that AHRE and higher AHRE burden were independent predictive factors for worsening HF. The high group showed a higher risk for HF than the non-AHRE groups, but no significant difference was found between the low- and non-AHRE groups. New-onset higher AHRE burden was associated with subsequent risk for HF in patients with CIEDs.

Sections du résumé

BACKGROUND
The relationship between atrial high-rate episode (AHRE) burden (i.e., the frequency of atrial tachyarrhythmia) and heart failure (HF) risk is unclear. We hypothesized that new-onset and higher burden of AHRE are associated with HF. Methods and Results: We included 104 consecutive patients with cardiac implantable electronic devices (CIEDs) capable of continuous atrial rhythm monitoring. Patients with AF history were excluded. To stratify patients, AHREs were evaluated only during the initial 1 year after CIED implantation. The primary endpoint was all-cause death or new-onset or worsening HF that required unplanned hospitalization or readjustment of HF drug therapy. At 1 year after CIED implantation, 34/104 patients (33%) exhibited AHREs. No difference in basal clinical characteristics except for left ventricular ejection fraction between patients with and without new-onset AHREs was found. AHRE groups had more HF events than the non-AHRE group. All patients were divided into 3 groups based on AHRE burden: none, low, and high. Worsening HF was observed in 12 patients (12%). Cox hazard analysis revealed that AHRE and higher AHRE burden were independent predictive factors for worsening HF. The high group showed a higher risk for HF than the non-AHRE groups, but no significant difference was found between the low- and non-AHRE groups.
CONCLUSIONS
New-onset higher AHRE burden was associated with subsequent risk for HF in patients with CIEDs.

Identifiants

pubmed: 30814400
doi: 10.1253/circj.CJ-18-1130
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

736-742

Auteurs

Ryo Nishinarita (R)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Shinichi Niwano (S)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Hidehira Fukaya (H)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Jun Oikawa (J)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Takeru Nabeta (T)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Gen Matsuura (G)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Yuki Arakawa (Y)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Shuhei Kobayashi (S)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Yuki Shirakawa (Y)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Ai Horiguchi (A)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Hironori Nakamura (H)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Naruya Ishizue (N)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Jun Kishihara (J)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Akira Satoh (A)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Junya Ako (J)

Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH